Skip to content
Abierto
Menu

Justification

Justification and Approval for Sole Source TPOXX Requirement

JA-24-Edg-173

Department of the Army, W6QK ACC-APG. Pharmaceutical Preparation Manufacturing.

View on SAM.govMarkdown

Awarded

Siga Technologies, Inc.

$1,091,797.50 obligated so far on USAspending, February 15, 2024, contract W911SR-22-C-0051

Description

As published on SAM.gov.

The purpose of this sole source within scope modification to Siga Technologies Inc., is to procure additional doses of TPOXX thereby replenishing existing National Stockpile quantities. TPOXX is an oral Smallpox Treatment in capsule form, approved by the United States Food and Drug Administration in 2018.

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Siga Technologies, Inc.
UEI
VJRNRTSL22K4
CAGE
1V4X4
Vendor location
New York, NY
Contract
W911SR22C0051, definitive contract
Obligated
$1,091,797.50, current value $11,752,417
Actions
1 between February 15, 2024 and February 15, 2024
Competition
Not Competed, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
To Deliver Courses of Tpoxx to Replenish the National Stockpile of Smallpox Treatments.
Match
award number W911SR22C0051 equals the contract number; same awarding office W911SR (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. February 22, 2024

    Justification

    SAM.gov, notice 02c302e2c4fd4b08b9d67fa8bc2e89e4

Points of contact

Also open from this buyer